Penetration of latamoxef, cefoperazone and piperacillin into the sputum of patients with cystic fibrosis.
Concentrations of latamoxef, cefoperazone and piperacillin, administered intravenously, were measured in serum and sputum of cystic fibrosis patients with recurrent pulmonary infections, chronically colonized with Pseudomonas aeruginosa. Serum pharmacokinetic data were consistent with prior reports. Peak sputum to peak serum concentrations were approximately 3% for each antimicrobial. However, the more prolonged sputum concentrations of piperacillin were reflected in greater areas under the sputum concentration-time curve and a longer duration above the MIC50 of tested P. aeruginosa strains for that drug.
D000293:Adolescent; D000328:Adult; D002438:Cefoperazone / Q000097:blood / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D009070:Moxalactam / Q000097:blood / Q000378:metabolism*; D010878:Piperacillin / Q000097:blood / Q000378:metabolism*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013183:Sputum / Q000378:metabolism*
D002438:Cefoperazone; D009070:Moxalactam; D010878:Piperacillin